Investors on the quest for market-beating returns often employ the strategy of stock picking. Making informed choices in stocks can greatly amplify your wealth.
As of close of business last night, UroGen Pharma Ltd’s stock clocked out at $5.00, up 3.31% from its previous closing price of $4.84. In other words, the price has increased by $3.31 from its previous closing price. On the day, 3.92 million shares were traded.
Ratios:
To gain a deeper understanding of URGN’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 5.47 and its Current Ratio is at 5.65.
On April 16, 2025, Scotiabank started tracking the stock assigning a Sector Outperform rating and target price of $23.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Jan 31 ’25 when Schoenberg Mark sold 4,551 shares for $11.14 per share. The transaction valued at 50,698 led to the insider holds 145,666 shares of the business.
Smith Jason Drew sold 7,379 shares of URGN for $82,202 on Jan 31 ’25. The General Counsel now owns 26,468 shares after completing the transaction at $11.14 per share. On Sep 09 ’24, another insider, Schoenberg Mark, who serves as the Chief Medical Officer of the company, sold 859 shares for $13.08 each. As a result, the insider received 11,236 and left with 145,091 shares of the company.
Valuation Measures:
For the stock, the TTM Price-to-Sale (P/S) ratio is 2.51.
Stock Price History:
Over the past 52 weeks, URGN has reached a high of $20.70, while it has fallen to a 52-week low of $3.42. The 50-Day Moving Average of the stock is -45.93%, while the 200-Day Moving Average is calculated to be -55.33%.
Shares Statistics:
A total of 46.10M shares are outstanding, with a floating share count of 38.89M. Insiders hold about 15.66% of the company’s shares, while institutions hold 91.87% stake in the company.
